Abstract 7898: Clinical benefit of the HIF-2α inhibitor casdatifan (Cas) across molecular subtypes in clear cell renal cell carcinoma (ccRCC) patients from the ARC-20 Clinical Study
Year: 2026
Type: conference-abstract
Source: Cancer Research
Authors: Benjamin Weeder, Yinghui Guan, Jaskirat Singh, Brian Rini, Toni K. Choueiri, Angelo Kaplan, Omar Kabbarah, Soonweng Cho
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7148785828
Cites:
Cited by:
Related to: